Page 1

( Mark One ) [ X ] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington , D.C. 20549 FORM 10 - Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 ( d ) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31 , 2021 [ ] OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 ( d ) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Delaware Commission File Number : 001-39796 Vivos Therapeutics , Inc. ( Exact name of registrant as specified in its charter ) 81-3224056 ( I.R.S. Employer Identification No. ) ( State or other jurisdiction of incorporation or organization ) 9137 Ridgeline Boulevard , Suite 135 Highlands Ranch , CO ( Address of principal executive offices ) Title of each class 80129 ( Zip Code ) Registrant's telephone number , including area code : ( 866 ) 908-4867 Securities registered pursuant to Section 12 ( b ) of the Act : Common stock , $ 0.0001 par value Trading Symbol ( s ) VVOS Name of exchange on which registered Nasdaq Capital Market Indicate by check mark whether the registrant ( 1 ) has filed all reports required to be filed by Section 13 or 15 ( d ) of the Securities Exchange Act of 1934 during the preceding 12 months ( or for such shorter period that the registrant was required to file such reports ) , and ( 2 ) has been subject to such filing requirements for the past 90 days . Yes [ X ] No [ ] Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S - T ( § 232.405 of this chapter ) during the preceding 12 months ( or for such shorter period that the registrant was required to submit such files ) . Yes [ X ] No [ ] Indicate by check mark whether the registrant is a large accelerated filer , an accelerated filer , a non - accelerated filer , a smaller reporting company , or an emerging growth company . See the definitions of “ large accelerated filer , ” “ accelerated filer , ” “ smaller reporting company , " and " emerging growth company ” in Rule 12b - 2 of the Exchange Act . Smaller reporting company Emerging growth company [ X ] Large accelerated filer ( ) Accelerated filer ( ) Non - accelerated filer [ X ] [ X ] If an emerging growth company , indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13 ( a ) of the Exchange Act . [ ] Indicate by check mark whether the registrant is a shell company ( as defined in Rule 12b - 2 of the Exchange Act ) . Yes [ ] No [ X ] As of May 14 , 2021 , the registrant had 22,812,119 shares of common stock , $ 0.0001 par value per share , outstanding .